CLAIMS

1. Use of an inhalable ultrarapid acting insulin (URAI) formulation comprising 3,6-di(N-fumaryl-4-aminobutyl)-2,5-diketopiperazine and recombinant human insulin in the preparation of a medicament for the treatment of diabetes in a patient, wherein the ultrarapid acting insulin is a dry powder provided in a cartridge comprising 4 units, 8 units or 12 units of ultrarapid acting insulin; and wherein the medicament is to be administered to the patient at mealtime and an initial dose is at least 4 units, and further wherein a supplemental dose of the URAI is to be administered by inhalation if blood glucose exceeds 140 mg/dl 60-120 minutes after administration of the mealtime dose.

2. The use of claim 1 wherein an initial dosage is 8 units.

3. The use of claim 1, further comprising measuring 2-hour post-prandial blood glucose.

4. The use of claim 3, further comprising measuring prandial blood glucose at mealtime on at least three days within one week.

5. The use of claim 4, further comprising measuring prandial blood glucose at mealtime on three consecutive days.

6. The use of claim 4, further comprising measuring prandial blood glucose at mealtime on seven consecutive days.

7. The use of claim 4, further comprising titrating up the dosage of the URAI preparation by increasing the dosage at mealtime by the amount of the initial dosage if 2-hour post-prandial median glucose is >110 mg/dl.

8. The use of claim 1 wherein the URAI formulation is to be administered by inhalation into the lungs.

9. The use of claim 1 wherein an initial supplemental dosage is 4 units.

10. The use of claim 1 wherein an initial supplemental dosage is 8 units.

11. The use of claim 1, further comprising measuring 2-hour post-prandial blood glucose.

12. The use of claim 11, further comprising measuring prandial blood glucose at mealtime on at least three days within one week.

13. The use of claim 11, further comprising measuring prandial blood glucose at mealtime on three consecutive days.

14. The use of claim 11, further comprising measuring prandial blood glucose at mealtime on seven consecutive days.

15. The use of claim 1 wherein the supplemental dose of the URAI formulation is to be administered by inhalation into the lungs.